G. Lacoste

Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.

J. Limacher, B. Acres, G. Lacoste, 2015, Current topics in microbiology and immunology.

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

M. Buyse, R. Ramlau, E. Stoelben, 2011, The Lancet. Oncology.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

E. Felip, J. Adam, A. Szczesna, 2016, The Lancet. Oncology.

TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC).

J. Nemunaitis, T. Burzykowski, E. Quoix, 2012 .

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.

J. Nemunaitis, E. Felip, L. Crinò, 2015 .

Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.

R. Dummer, C. Rochlitz, P. Romero, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial

J. Limacher, C. Rotonda, F. Bonnetain, 2015, PloS one.

Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010.

R. Ramlau, J. Limacher, E. Quoix, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.